Clinical Research Directory

Inclusion Criteria: * Aged ≥ 18 years * Able to provide written informed consent * Histological diagnosis of colorectal cancer with evidence of liver metastases * Planned liver resection surgery for colorectal cancer liver metastases with curative intent, including repeat 're-do' colorectal cancer liver metastases surgery (a second independent resection for a separate colorectal cancer liver recurrence) * Intention to receive IMP prior to colorectal cancer liver metastases surgery Exclusion Criteria: * Previous CRCLM surgery for the management of the current metastatic disease * Incurable extra-hepatic metastases * Current (in the last 2 months) or planned regular (\>3 doses per week) use of O3FA-containing drugs or supplements, including Vazkepa®, Omacor®, fish oil and cod-liver oil supplements * Fish/seafood allergy * Diagnosis of hereditary fructose intolerance * Soya or peanut allergy * Inability to comply with trial treatment and follow-up schedule * Known bleeding tendency/condition (e.g. von Willebrand disease) * A previous malignancy within the last 5 years other than: * colorectal cancer * non-melanoma skin cancer where treatment consisted of resection only or radiotherapy * ductal carcinoma in situ (DCIS) where treatment consisted of resection only * cervical carcinoma in situ where treatment consisted of resection only * superficial bladder carcinoma where treatment consisted of resection only * A previous malignancy where the patient has been disease free for ≤ 5 years * Pregnant or breastfeeding women or women of childbearing potential not willing to use effective contraceptive measures. Women of childbearing potential are defined as fertile, following menarche and until becoming post-menopausal, unless permanently sterile * Men defined as fertile (post-pubescent and not permanently sterile by vasectomy or bilateral orchidectomy) and not willing to use effective contraceptive measures if appropriate.